Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.

What: Shares of Omnicell (NASDAQ:OMCL), an automated medication and supply management solutions provider to the health care industry, popped as much as 13% after reporting its fourth-quarter earnings results.

So what: For the quarter, Omnicell recorded a whopping 43% increase in revenue to $90.2 million and adjusted earnings of $0.25. Although EPS was in line with expectations, sales came in $3.1 million higher than Wall Street had expected. Omnicell's management attributed record revenue and bookings in its acute care segment for its record year and is looking forward to further utilizing its acquisition of MTS Medication Technologies last year to fuel growth in 2013.

Now what: This isn't rocket science; Omnicell is in the right business at the right time. Health records and almost all things health care are being moved online and digitization of medications and product supply management is a mandate. Even after today's pop, at just 14 times forward earnings Omnicell could represent quite a bargain, and I'd suggest keeping it high up on your watchlist.

Craving more input? Start by adding Omnicell to your free and personalized watchlist so you can keep up on the latest news with the company.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis -- even one of our own -- helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.